With the establishment of the theory of breast cancer as a systemic disease, breast surgery has started to develop in the direction of humanized, minimally invasive, and personalized “triple” treatment, such as breast-conserving, axillary-conserving, and ovary-conserving “triple” treatment. The further improvement of “triple” and “triple” treatment techniques and methods for breast cancer will benefit more and more breast cancer patients. Yi Tongbo, Breast Surgery Department, Taizhou People’s Hospital On the basis of the success of breast-conserving surgery, breast surgery has developed in the direction of axillary conservation, and the sentinel lymph node biopsy (SLNB) technique was born. As the first lymph node with orderly metastasis, if there is no metastasis in the sentinel lymph node (SLN), theoretically, there should be no metastasis in other non-SLNs, and conventional axillary lymph node dissection is not necessary. At present, the success rate and accuracy of SLNB can reach more than 95%, and some famous oncology research centers have started to apply this technique in clinical practice, and the axilla is no longer cleared for SLN-negative patients. Ovarian ablation (OA) includes surgical, radiological and pharmacological methods. Ovariectomy debulking for premenopausal metastasis breast cancer (MBC) was first reported successfully by Beatson in 1896. However, it was not until 1966, when Jensen et al. discovered the estrogen receptor (ER), that OA was accurately and universally performed. Although the effect of surgical debulking was once and for all, the osteoporosis and cardiovascular disease associated with early menopause would be lifelong and irreversible, making it difficult for patients to accept. Radiation debridement began in the 1930s and is an effective alternative to surgical debridement, but the effect is slow and incomplete, and the efficacy is influenced by radiation dose, program and age, with a failure rate of 35% in young patients (<35). Although menstruation may resume in 7% of patients after radiation debulking, early menopause is irreversible. In the early 1970s, Schally et al. isolated luteinizing hormone releasing hormone (LHRH), and LHRH analog (LHRHa), which has a pharmacological depot effect, became unique in the treatment of breast cancer. LHRHa binds to the pituitary receptor, leading to the down-regulation of the receptor, thus inhibiting the synthesis and release of luteinizing hormone (LH) and follicular stimulating hormone (FSH), lowering the ovarian secretion of estradiol to the postmenopausal level and achieving the effect of ovariectomy debulking, but the osteoporosis and cardiovascular side effects are mild and reversible. However, the side effects of osteoporosis and cardiovascular surgery are mild and reversible, and the ovaries are preserved, which patients are happy to accept.